HZ-H08905 / HealZen Therap - LARVOL DELTA

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study (ASH 2024) - "Monotherapy of HZ-H08905 was well tolerated and demonstrated significant efficacy in patients with R/R PTCL in phase I study. Currently, a randomized, double-blind, active-controlled phase 3 study is ongoing in China to evaluate HZ-H08905 in patients with R/R PTCL as a pivotal study."

Clinical • P1 data • Anemia • Cardiovascular • Chronic Lymphocytic Leukemia • Dermatitis • Dermatology • Diffuse Large B Cell Lymphoma • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Immunology • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Oncology • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • PIK3CD

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study (ASH 2024) - "Among the 12 patients with FL, the ORR was 83.3% (10/12) and CRR was 50.0% (6/12). Conclusions : These results demonstrated that HZ-H08905 monotherapy was well tolerated and showed significant efficacy in patients with R/R BCM, particularly R/R FL."

Clinical • P1 data • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Indolent Lymphoma • Infectious Disease • Leukopenia • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia • PIK3CD

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies (ASH 2023) - "These results demonstrated that HZ-H08905 monotherapy was well tolerated and showed promising efficacy in patients with R/R NHL. A Phase 2 R/R PTCL registration study in China is currently planned."

Clinical • P1 data • PK/PD data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Varicella Zoster • PIK3CD

A Double-blineded, Randomized, Multi-center Phase III Clinical Study of HZ-H08905 Versus Chidamide in Patients With Relapsed/Refractory PTCL (ChiCTR) - P3 | N=140 | Recruiting | Sponsor: Beijing Cancer Hospital/The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou HealZen Therapeutics Co., Ltd

New P3 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8